File: '\\swfile\EmailIn\20250117 131437 Attachment 2025_01_17 TRUE NR Announcing IR provider.docx'

Treatment

TREATMENT.COM AI INC. ENGAGES TAFIN GMBH FOR INVESTOR RELATIONS SERVICES

Vancouver, British Columbia, January 17, 2025 - Treatment.com AI Inc. (the "Company" or "Treatment") (CSE: TRUE; OTC: TREIF; FFA: 939) announces that it has engaged TAFIN GmbH (TAFIN") to provide investor relations services tailored to a German investor audience for an initial period of three months commencing on January 17, 2025, in consideration of EUR 150,000.

TAFIN shall utilize digital marketing and online advertisements through Google, Facebook and Instagram, third-party newsletters, as well as other digital marketing on various third-party websites. TAFIN does not currently own any interest, directly or indirectly, in the Company or its securities. TAFIN's address is 65232 Taunusstein, Germany (phone: +49 6128 9792946, email: tafin@finanzmedien.gmbh). TAFIN and its directors and officers are arm's length from the Company.

About Treatment.com AI Inc.

Treatment.com AI is a company utilizing AI and best clinical practices to positively disrupt the healthcare sector and impact current inefficiencies and challenges. With the input of hundreds of healthcare professionals globally, Treatment has built a comprehensive, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing highly qualified clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), x-rays, and billing codes. The GLM helps healthcare professionals (doctor, nurse or pharmacist) reduce their administrative burden; create more time for needed face to face patient appointments and has the propensity for greater consistency in quality of patient support. Treatment's GLM platform also brings the possibility of health equity and inclusion for disenfranchised communities. To learn more about Treatment's products and services: www.treatment.com or email: info@treatment.com

FOR ADDITIONAL INFORMATION, CONTACT:

Dr. Essam Hamza, CEO

ehamza@treatment.com

For media inquiries, contact: media@treatment.com

Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-895

Cautionary Statement

This news release contains forward-looking statements relating to the future operations of Treatment and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, are forward- looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from Treatment's expectations include other risks detailed from time to time in the filings made by Treatment with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Treatment. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Treatment will only update or revise publicly the included forward-looking statements as expressly required by Canadian securities law.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.